Seaport Therapeutics and Hemab Therapeutics are poised to join the ranks of publicly traded companies, with both biopharmaceutical firms announcing…
Read More
Eli Lilly Acquires Ajax Therapeutics for Up to $2.3 Billion in Strategic Move to Bolster Oncology Pipeline
Eli Lilly and Company has significantly expanded its oncology portfolio with the definitive agreement to acquire Ajax Therapeutics, a clinical-stage…
Read More
Enanta Pharmaceuticals Poised to Lead Emerging RSV Therapeutics Market as Zelicapavir Advances to Phase III
Enanta Pharmaceuticals is strategically positioned to capture a significant share of the largely undeveloped market for respiratory syncytial virus (RSV)…
Read More
Ray Therapeutics Secures $125 Million Series B Funding to Accelerate Vision Restoration Pipeline
Ray Therapeutics, a biopharmaceutical company at the forefront of developing novel gene therapies for vision restoration, has successfully closed a…
Read More
Eli Lilly Expands In Vivo Gene Therapy Arsenal with $7 Billion Acquisition of Kelonia Therapeutics
Eli Lilly and Company has significantly bolstered its position in the rapidly evolving cell and gene therapy (CGT) landscape with…
Read More
UCB Acquires Neurona Therapeutics for Up to $1.15 Billion to Bolster Epilepsy Pipeline with Regenerative Cell Therapy
BRUSSELS, BELGIUM & SAN FRANCISCO, USA – April 20, 2026 – Global biopharmaceutical leader UCB has finalized a definitive agreement…
Read More
Daiichi Sankyo Partners with Interna Therapeutics to Revolutionize Targeted Drug Delivery with Molecular Nano Motor Technology
Boston, MA & Tokyo, Japan – April 17, 2026 – In a significant move to enhance the precision and efficacy…
Read More
Aligos Therapeutics Licenses Pevifoscorvir Sodium to Xiamen Amoytop Biotech for Greater China, Bolstering HBV Treatment Landscape
Aligos Therapeutics has entered into an exclusive licensing agreement with Xiamen Amoytop Biotech, granting the Chinese biopharmaceutical company the rights…
Read More
Kailera Therapeutics Secures $625 Million in Landmark IPO to Accelerate Obesity Drug Development
Obesity-focused biotechnology firm Kailera Therapeutics has successfully launched its Initial Public Offering (IPO), raising an impressive $625 million. This significant…
Read More
Roche and C4 Therapeutics Forge Strategic Alliance to Pioneer Degrader-Antibody Conjugates for Novel Cancer Therapies
Roche and C4 Therapeutics Forge Strategic Alliance to Pioneer Degrader-Antibody Conjugates for Novel Cancer Therapies Roche, a global pharmaceutical giant,…
Read More
